Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Growth Metrics
Income Statement
Others
Ratios

Skinvisible (SKVI) Change in Accured Expenses (2016 - 2026)

Skinvisible's Change in Accured Expenses history spans 16 years, with the latest figure at $97013.0 for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 133.32% to $97013.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $394676.0, a 6.1% decrease, with the full-year FY2025 number at $394676.0, down 6.1% from a year prior.
  • Change in Accured Expenses hit $97013.0 in Q4 2025 for Skinvisible, up from $75504.0 in the prior quarter.
  • Over the last five years, Change in Accured Expenses for SKVI hit a ceiling of $490421.0 in Q3 2024 and a floor of -$291120.0 in Q4 2024.
  • Historically, Change in Accured Expenses has averaged $84237.4 across 5 years, with a median of $92613.0 in 2022.
  • Biggest five-year swings in Change in Accured Expenses: skyrocketed 1479.14% in 2022 and later crashed 363.82% in 2024.
  • Tracing SKVI's Change in Accured Expenses over 5 years: stood at $5763.0 in 2021, then skyrocketed by 1479.14% to $91006.0 in 2022, then rose by 21.25% to $110349.0 in 2023, then crashed by 363.82% to -$291120.0 in 2024, then soared by 133.32% to $97013.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for SKVI at $97013.0 in Q4 2025, $75504.0 in Q3 2025, and $121828.0 in Q2 2025.